Non-interventional Study to Observe Treatment Efficacy in Maintaining Symptoms Control in Patients With Schizophrenia, Treated With Seroquel XR

AstraZeneca1 site in 1 country578 target enrollmentAugust 2008

Overview

the primary purpose of the study is to observe symptoms control in schizophrenia for 6 months in patients treated with Seroquel XR.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Registry

clinicaltrials.gov

Start Date

August 2008

End Date

September 2009

Last Updated

16 years ago

Study Type

Observational

Sex

All

Sponsor

•Patients will have a diagnosis of schizophrenia , as defined by DSM-IV-TR and their symptoms are controlled with Seroquel XR therapy started approximately 1 month before
•All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme.

•All the patients who have a known hypersensitivity to Seroquel XR/quetiapine or any of its excipients will not be included in this study.
•As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.

Brief Psychiatric Rating Scale - BPRS

Time Frame: monthly/ at every clinic visit- 7 times

Clinical Global Impression Severity of Illness - CGI -S(monthly/ at every clinic visit- 7 times)
Clinical Global Impression Improvement CGI -I(monthly/ at every clinic visit except first visit- 6 times)
Quality of Life Enjoyment & Satisfaction Questionnaire - Short Form ( Q - LES - Q - SF)(twice/first and last clinic visit)